Wire · opportunities
OncoSil Medical Receives FDA Exemption Approval for Targeted Radiation Device
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
OncoSil Medical received FDA humanitarian device exemption approval for its targeted radiation device to treat the rare bile duct cancer distal cholangiocarcinoma, enabling a US market entry aimed at about 1,000 patients yearly and an $80 million market. The device will launch in late 2027 with a restricted rollout and post-approval study to assess safety and benefits.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 17 Aug 2026 and 18 Aug 2026.
◆ ◆ The Wire takeaway
You can now access the US market for rare bile duct cancer treatment by aligning with the post-approval study and early specialist centres. Rapidly building training and support will determine your chance to capture adoption in this underserved oncology niche.
◆ Coverage
4 sources · first reported 17 Aug 2026 · latest 18 Aug 2026
◆ Related on Wire
◆ Topics